Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2005

View Archived Issues

NIH accepts clinical study of Zestra

CombinatoRx and HenKan sign Asian agreement for CRx-026

Alexza Molecular Delivery changes name to Alexza Pharmaceuticals

Clinical evidence confirms the survival benefits of Provenge in advanced prostate cancer

ARIES-2 study of ambrisentan completes enrollment

ACT 3 atrial fibrillation study of RSD-1235 completes enrollment

Pivotal study of MBP-8298 expands into Europe

FDA requests information on phase II study of arimoclomol for ALS

Schwarz Pharma acquires remaining rights to rotigotine

Kirin Brewery acquires Hematech

XL-820 enters phase I study in solid tumors

ONO-4128 begins phase III trials in treatment-experienced HIV patients

Schering-Plough to acquire from Millennium exclusive U.S. Integrilin rights

Progress in NicOx ophthalmology collaboration with Pfizer

IGN-311 begins new study, subject of new Asian licensing agreement

M-2000: a novel, safe and efficacious NSAID for arthritis

Wockhardt reports successful progression of new quinolone into clinical trials

MC4 receptor agonist shows in vivo efficacy for obesity and sexual dysfunction

In vitro and in vivo effects of novel DPP-IV inhibitor KR-62436

NITD to test Alfacell's AC 03-636 for Dengue fever

FDA issues public health advisory for mifepristone

New agents for treating hepatitis C infection disclosed

Recent Sumitomo patent reports new treatments for skin and allergic diseases

Update on the antitumor efficacy and safety of pemetrexed

New clinical data on the survival effects of bexarotene in advanced NSCLC

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...